Immunotherapy is the latest method of pharmaceutical treatment that opened the whole new era in oncology. In 2018 an American James P. Allison and a Japanese Tasuku Honjo were awarded the Nobel Prize for their discovery of biochemical markers that can be influenced with immunotherapy, – they are called cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and programmed death-ligand 1 (PD-L1).
Immunotherapy has proven its effectiveness in the palliative treatment of breast cancer: in combination with chemotherapy some immune drugs have increased the treatment efficacy by tens of percent. However, using immunotherapy requires a chemotherapist with experience – both the treatment and the side effects have certain specific features. Doctors at LISOD have this experience.